MESO has been the topic of a number of other reports. HC Wainwright set a $7.00 price objective on shares of Mesoblast and gave the company a buy rating in a research note on Friday, August 30th. Maxim Group reiterated a buy rating and issued a $16.00 target price on shares of Mesoblast in a report on Thursday, September 12th. Zacks Investment Research lowered shares of Mesoblast from a buy rating to a hold rating in a report on Friday, September 6th. Chardan Capital set a $6.00 target price on shares of Mesoblast and gave the stock a hold rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the stock a buy rating in a report on Tuesday, September 10th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Mesoblast currently has an average rating of Buy and a consensus price target of $11.67.
Shares of MESO stock opened at $7.10 on Monday. Mesoblast has a 52-week low of $3.35 and a 52-week high of $8.78. The stock has a market cap of $668.61 million, a PE ratio of -7.80 and a beta of 1.77. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.41 and a current ratio of 1.41. The firm’s 50 day moving average price is $5.29 and its two-hundred day moving average price is $5.17.
Mesoblast (NASDAQ:MESO) last announced its quarterly earnings data on Thursday, August 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. The firm had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $1.31 million. As a group, sell-side analysts predict that Mesoblast will post -0.72 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley increased its stake in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 147,702 shares of the company’s stock after acquiring an additional 109,295 shares during the period. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 as of its most recent SEC filing. 2.76% of the stock is owned by institutional investors.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Article: What are no-load funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.